Beijing Science Sun Pharmaceutical Co., Ltd. (SHE:300485)
China
· Delayed Price · Currency is CNY 10.91
-0.09 (-0.82%)
Apr 30, 2026, 1:55 PM CST
SHE:300485 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 398.32 | 414.95 | 475.92 | 733.73 | 1,050 | Upgrade
|
| Other Revenue | 6.4 | 1.53 | 0.65 | 0.82 | 1.15 | Upgrade
|
| Revenue | 404.72 | 416.48 | 476.57 | 734.55 | 1,051 | Upgrade
|
| Revenue Growth (YoY) | -2.82% | -12.61% | -35.12% | -30.10% | -3.97% | Upgrade
|
| Cost of Revenue | 147.59 | 143.23 | 140.94 | 171.61 | 182.12 | Upgrade
|
| Gross Profit | 257.13 | 273.26 | 335.63 | 562.94 | 868.68 | Upgrade
|
| Selling, General & Admin | 197.43 | 199.12 | 292.63 | 429.92 | 658.62 | Upgrade
|
| Research & Development | 69.51 | 46.22 | 77.73 | 100.63 | 103.84 | Upgrade
|
| Other Operating Expenses | 8.33 | 6.65 | 6.61 | 8.76 | 11.74 | Upgrade
|
| Operating Expenses | 274.38 | 250.81 | 375.38 | 538.7 | 773.27 | Upgrade
|
| Operating Income | -17.25 | 22.44 | -39.75 | 24.24 | 95.41 | Upgrade
|
| Interest Expense | -0.45 | - | - | - | - | Upgrade
|
| Interest & Investment Income | 29.55 | 1.71 | 60.91 | 87.19 | 144.34 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.35 | 0 | 0 | -0 | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.03 | 0.25 | -0.05 | -0.33 | -0.26 | Upgrade
|
| EBT Excluding Unusual Items | 12.18 | 24.4 | 21.11 | 111.1 | 239.49 | Upgrade
|
| Gain (Loss) on Sale of Investments | 8.61 | -108.13 | 100.27 | 125.41 | 185.65 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.11 | - | 0 | 6.65 | 6.57 | Upgrade
|
| Asset Writedown | -11.38 | - | - | -0.04 | -0 | Upgrade
|
| Other Unusual Items | 2.75 | 0.1 | 0.74 | 11.43 | 7.2 | Upgrade
|
| Pretax Income | 12.3 | -83.57 | 122.16 | 254.62 | 439.02 | Upgrade
|
| Income Tax Expense | 4.51 | -6.69 | 25.76 | 51.97 | 43.89 | Upgrade
|
| Earnings From Continuing Operations | 7.79 | -76.87 | 96.41 | 202.65 | 395.13 | Upgrade
|
| Minority Interest in Earnings | 6.78 | 8.02 | 6.51 | 2.09 | 7.14 | Upgrade
|
| Net Income | 14.57 | -68.85 | 102.92 | 204.73 | 402.27 | Upgrade
|
| Net Income to Common | 14.57 | -68.85 | 102.92 | 204.73 | 402.27 | Upgrade
|
| Net Income Growth | - | - | -49.73% | -49.10% | 159.69% | Upgrade
|
| Shares Outstanding (Basic) | 486 | 492 | 490 | 476 | 479 | Upgrade
|
| Shares Outstanding (Diluted) | 486 | 492 | 490 | 476 | 479 | Upgrade
|
| Shares Change (YoY) | -1.24% | 0.35% | 2.93% | -0.58% | -1.07% | Upgrade
|
| EPS (Basic) | 0.03 | -0.14 | 0.21 | 0.43 | 0.84 | Upgrade
|
| EPS (Diluted) | 0.03 | -0.14 | 0.21 | 0.43 | 0.84 | Upgrade
|
| EPS Growth | - | - | -51.16% | -48.81% | 162.50% | Upgrade
|
| Free Cash Flow | -73.2 | 34.85 | -31.7 | 67.15 | 137.38 | Upgrade
|
| Free Cash Flow Per Share | -0.15 | 0.07 | -0.07 | 0.14 | 0.29 | Upgrade
|
| Dividend Per Share | 0.300 | - | 0.022 | 0.086 | 0.168 | Upgrade
|
| Dividend Growth | - | - | -74.42% | -48.81% | 158.46% | Upgrade
|
| Gross Margin | 63.53% | 65.61% | 70.43% | 76.64% | 82.67% | Upgrade
|
| Operating Margin | -4.26% | 5.39% | -8.34% | 3.30% | 9.08% | Upgrade
|
| Profit Margin | 3.60% | -16.53% | 21.60% | 27.87% | 38.28% | Upgrade
|
| Free Cash Flow Margin | -18.09% | 8.37% | -6.65% | 9.14% | 13.07% | Upgrade
|
| EBITDA | 29.66 | 69.34 | 8.64 | 71.64 | 151.09 | Upgrade
|
| EBITDA Margin | 7.33% | 16.65% | 1.81% | 9.75% | 14.38% | Upgrade
|
| D&A For EBITDA | 46.9 | 46.9 | 48.39 | 47.39 | 55.68 | Upgrade
|
| EBIT | -17.25 | 22.44 | -39.75 | 24.24 | 95.41 | Upgrade
|
| EBIT Margin | -4.26% | 5.39% | -8.34% | 3.30% | 9.08% | Upgrade
|
| Effective Tax Rate | 36.69% | - | 21.08% | 20.41% | 10.00% | Upgrade
|
| Revenue as Reported | 404.72 | 416.48 | 476.57 | 734.55 | 1,051 | Upgrade
|
| Advertising Expenses | - | - | 2.4 | 137.51 | 293.09 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.